Head-To-Head Comparison: Halo Labs (OTCMKTS:WSLFF) and Milestone Pharmaceuticals (NASDAQ:MIST)

Halo Labs (OTCMKTS:WSLFF) and Milestone Pharmaceuticals (NASDAQ:MIST) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Earnings and Valuation

This table compares Halo Labs and Milestone Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halo Labs	N/A	N/A	N/A	N/A	N/A
Milestone Pharmaceuticals	$1.55 million	91.17	-$63.06 million	($0.69)	-1.64

Halo Labs has higher earnings, but lower revenue than Milestone Pharmaceuticals.

Insider & Institutional Ownership

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Halo Labs and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halo Labs	N/A	N/A	N/A
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Analyst Recommendations

This is a summary of current recommendations and price targets for Halo Labs and Milestone Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halo Labs	0	0	0	0	0.00
Milestone Pharmaceuticals	1	1	4	1	2.71

Milestone Pharmaceuticals has a consensus price target of $6.40, suggesting a potential upside of 463.88%. Given Milestone Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Halo Labs.

Summary

Milestone Pharmaceuticals beats Halo Labs on 7 of the 9 factors compared between the two stocks.

About Halo Labs

Westleaf Inc., an integrated cannabis company, engages in the cultivation, extraction, production, and retail sale of cannabis derivatives in Canada. It operates four retail stores under the Prairies Records name in Saskatchewan and Alberta, as well as an e-commerce operation in Saskatchewan. The company is headquartered in Calgary, Canada.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.